No pain, no gain: Galena buys US Abstral rights from Orexo
This article was originally published in Scrip
Executive Summary
While Galena Biopharma awaits three-year data for its cancer vaccine NeuVax (nelipepimut-S), the company will take on $15 million in new debt to generate near-term revenue from the acquisition of US rights to Orexo's Abstral (fentanyl) sublingual tablets for cancer pain.